In the BioHarmony Drug Report Database

"Preview" Icon

Ibandronate

Boniva, Bondronat, Bonviva (ibandronic acid) is a small molecule pharmaceutical. Ibandronic acid was first approved as Boniva on 1996-06-25. It is used to treat postmenopausal osteoporosis in the USA. It has been approved in Europe to treat bone fractures, breast diseases, breast neoplasms, calcium metabolism disorders, and hypercalcemia amongst others. It is known to target farnesyl pyrophosphate synthase. Boniva’s patent is valid until 2023-05-06 (FDA).

 

Trade Name

 

Bondronat, Bonviva
 

Common Name

 

ibandronic acid
 

ChEMBL ID

 

CHEMBL997
 

Indication

 

bone fractures, breast diseases, breast neoplasms, calcium metabolism disorders, hypercalcemia, neoplasm metastasis, neoplasms by site, neoplastic processes, postmenopausal osteoporosis, water-electrolyte imbalance, wounds and injuries
 

Drug Class

 

Androgens

Image (chem structure or protein)

Ibandronate structure rendering